Table 4.
Eligibility of HBsAg-positive people for treatment according to guidelines
|
AASLD (n=4) |
EASL 2012 (n=8) |
EASL 2017 (n=2) |
WHO (n=2) |
Other*(n=16) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Studies available | Eligible patients | Studies available | Eligible patients | Studies available | Eligible patients | Studies available | Eligible patients | Studies available | Eligible patients | |
| Year of publication | ||||||||||
| 2007–11 (n=50) | 2 (4%) | 12% (10–14) | 1 (2%) | 18% (16–20) | .. | .. | .. | .. | 4 (8%) | 15% (13–17) |
| 2012–18 (n=112) | 2 (2%) | 3% (2–4) | 7 (6%) | 20% (18–21) | 2 (2%) | 18% (15–22) | 2 (2%) | 10% (7–13) | 12 (11%) | 20% (19–21) |
| Recruitment setting | ||||||||||
| Outpatient (n=54) | 2 (4%) | 12% (11–14) | 4 (7%) | 19% (17–20) | 1 (2%) | 23% (18–27) | 1 (2%) | 10% (6–13) | 7 (13%) | 19% (17–20) |
| Inpatients (n=68) | .. | .. | 2 (3%) | 29% (25–33) | 1 (1%) | 23% (18–27) | 1 (1%) | 10% (6–13) | 9 (13%) | 21% (20–22) |
| Population based (n=11)† | 2 (18%) | 3% (2–4) | 1 (9%) | 4% (3–5) | .. | .. | .. | .. | .. | .. |
| Community (n=21)‡ | 1 (5%) | 6% (3–9) | 1 (5%) | 19% (2–26) | .. | .. | .. | .. | 3 (14%) | 13% (10–16) |
| Special groups (n=20) | .. | .. | 1 (5%) | 12% (6–18) | 1 (5%) | 6% (2–11) | 1 (5%) | 10% (4–16) | 1 (5%) | 12% (8–16) |
| WHO region | ||||||||||
| American (n=34) | 1 (3%) | 19% (13–24) | 2 (6%) | 36% (33–39) | .. | .. | .. | .. | 4 (12%) | 22% (20–24) |
| African (n=46) | 1 (2%) | 3% (2–4) | 5 (11%) | 18% (16–19) | 2 (4%) | 18% (14–22) | 2 (4%) | 10% (7–13) | 4 (9%) | 15% (13–17) |
| Eastern Mediterranean (n=33) | .. | .. | 1 (3%) | 19% (2–26) | .. | .. | .. | .. | 3 (9%) | 16% (14–18) |
| European (n=51) | .. | .. | 4 (8%) | 32% (29–35) | .. | .. | .. | .. | 6 (12%) | 22% (20–24) |
| Southeast Asia (n=40) | 1 (2%) | 6% (3–10) | 2 (5%) | 22% (18–25) | .. | .. | .. | .. | 5 (12%) | 18% (16–19) |
| Western Pacific (n=72) | 2 (3%) | 11% (9–12) | 3 (4%) | 25% (24–27) | .. | .. | .. | .. | 8 (11%) | 17% (16–18) |
| Overall (N=162) | 4 (2%) | 8% (7–9) | 8 (5%) | 19% (19–20) | 2 (1%) | 18% (14–22) | 2 (1%) | 10% (7–13) | 16 (10%) | 19% (18–20) |
Data are n (%) or % (95% CI). AASLD=American Association for the study of Liver Diseases. EASL=European Association for the Study of the Liver.
*
Studies used guidelines other than AASLD, EASL, or WHO, or used mixed guidelines to document treatment eligibility.
†
Studies of individuals not seeking care sampled using statistically representative methods.
‡
Studies of individuals not seeking care but recruited without statistically representative methods.